Business, energy, technology, markets and global industry news from Business News Today

AH-008

PharmaDeviceNews AH-008
AnHorn Medicines has begun first-in-human testing of AH-008 as the biotechnology company investigates whether the experimental therapy could help prevent chemotherapy-induced peripheral neuropathy. Representative image.
Pharma & Biotech

AnHorn Medicines doses first participant in Phase 1 AH-008 CIPN prevention trial

AnHorn Medicines doses the first participant in a Phase 1 AH-008 study, opening a cautious clinical test of chemotherapy neuropathy prevention.

Read More